PLXStockProtalix BioTherapeutics, Inc.
Verdicts genuinely change. Free email alert the moment PLX's does — no target price to set, unlike a price alert.
Near limit Ratio screen, 7 of 7 decided standards passing. MSCI Islamic is within 3 points of its line. Even if it crossed, the majority verdict would stay Compliant. What would change it
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Protalix BioTherapeutics, Inc. (PLX) is currently considered halal (Sharia-compliant), per our in-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 433 compliant Healthcare stocks we track. See compliant Healthcare stocks →
Still fetching analyst coverage — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.
How the status reached this point
Compliant · status tracked since Nov 17, 2026
No change to PLX’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.
Read once a day from our own screen, last on Nov 18, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $242.8M as of 2026-11-18. At the 2026-11-19 close it is about $251.3M (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 3.6% (3.8% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 8.8% (9.1% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.
Business activity: cleared (no excluded categories detected)
AAOIFI Pass 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.77% | 30.00% | Pass(26.2pp buffer) |
| Interest-bearing investments | 9.07% | 30.00% | Pass(20.9pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Usmani Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 7.73% | 33.00% | Pass(25.3pp buffer) |
| Interest-bearing investments | 18.64% | 33.00% | Pass(14.4pp buffer) |
| Non-liquid assets | 69.60% | at least 20.00% | Pass(49.6pp above the floor) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
MSCI Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 7.73% | 33.33% | Pass(25.6pp buffer) |
| Cash + interest-bearing securities | 18.64% | 33.33% | Pass(14.7pp buffer) |
| Accounts receivable | 30.40% | 33.33% | Pass(2.9pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
FTSE Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 18.64% | 33.33% | Pass(14.7pp buffer) |
| Accounts receivable | 30.40% | 50.00% | Pass(19.6pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Dow Jones Islamic Market Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 5.39% | 33.00% | Pass(27.6pp buffer) |
| Cash + interest-bearing securities | 12.99% | 33.00% | Pass(20.0pp buffer) |
| Accounts receivable | 8.20% | 33.00% | Pass(24.8pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
S&P Shariah Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.41% | 33.00% | Pass(26.6pp buffer) |
| Cash + interest-bearing securities | 15.46% | 49.00% | Pass(33.5pp buffer) |
| Accounts receivable | 9.76% | 49.00% | Pass(39.2pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
MSCI M-Series Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.41% | 33.33% | Pass(26.9pp buffer) |
| Cash + interest-bearing securities | 15.46% | 33.33% | Pass(17.9pp buffer) |
| Accounts receivable | 25.22% | 49.00% | Pass(23.8pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from PLX's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $52.7M | 2026-09-30 | Revenues |
| Interest-bearing debtShort and long-term borrowings | $0 | 2026-09-30 | no debt tag reported in 3+ years (treated as $0) |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $22.0M | 2026-09-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
| Total assetsBalance sheet total | $118.2M | 2026-09-30 | Assets |
| Market capDenominator for AAOIFI | $242.8M | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $145.6M | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $172.0M | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $0 | 2026-09-30 | no interest-income tag reported in 3+ years (treated as $0) |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-10, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-03-18, period ended 2026-09-30. Screened 2026-11-18.
-
Total assets$118.2M
Assets· period ended 2026-09-30 · 10-Q filed 2026-11-10 -
Interest-bearing debt$0
no debt tag reported in 3+ years (treated as $0)· balance sheet as of 2026-09-30 · no filing link for this figure -
Cash and interest-bearing securities$22.0M
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents· period ended 2026-09-30 · 10-Q filed 2026-11-10 -
Receivables$13.9M
AccountsReceivableNetCurrent· period ended 2026-09-30 · 10-Q filed 2026-11-10 -
Revenue$52.7M
Revenues· period ended 2025-12-31 · 10-K filed 2026-03-18 -
Interest income (non-permissible)$0
no interest-income tag reported in 3+ years (treated as $0)· income statement as of 2026-09-30 · no filing link for this figure -
Market cap$242.8MMarket quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-18 · not a filing figure, so no link
4 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.
What changed, and when
Verdict history for PLX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-11-15 Fail → Pass filing re-screen
- 2026-11-15 Unverified → Pass filing re-screen
Tracked since 2026-09-07.
What would change the status
The headline verdict is the majority of the decided ratio standards — 7 pass and 0 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-18.
Within 3 points of the line
- MSCI Islamic receivables ratio: 2.9pp buffer
MSCI Islamic is within 3 points of its line. Even if it crossed, the majority verdict would stay Compliant.
The ratios that move with the share price
AAOIFI's debt ratio (3.8% against a 30% line) would only fail if the market cap fell by 87%, to $30.5M. At the 2026-11-19 close it would read 3.6%.
AAOIFI's investments ratio (9.1% against a 30% line) would only fail if the market cap fell by 70%, to $73.5M. At the 2026-11-19 close it would read 8.8%.
Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.
Shariah-compliant alternatives
Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| VRTXVertex Pharmaceuticals, Inc. | $121.1B | $520.66-2.94% |
| REGNRegeneron Pharmaceuticals, Inc. | $85.3B | — |
| ARGXArgen X SE - ADR | $64.3B | — |
| ONCBeOne Medicines Ltd. American Depositary Shares | $40.4B | — |
| ALNYAlnylam Pharmaceuticals Inc | $31.6B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Peter Brown | Renaissance Technologies | $3M | 0.0% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $1M | 0.0% | 2026-09-30 |
| Steven Cohen | Point72 Asset Management | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 60.60 | NEUTRAL |
| Stochastic %K (14) | 82.61 | SELL |
| CCI (20) | 101.67 | SELL |
| Williams %R (14) | -17.39 | SELL |
| MACD (12,26,9) | 0.04 | BUY |
| ROC (10) | 12.27 | BUY |
| Momentum (10) | 0.33 | BUY |
| EMA (10) | 2.89 | BUY |
| SMA (10) | 2.85 | BUY |
| EMA (20) | 2.80 | BUY |
| SMA (20) | 2.72 | BUY |
| EMA (30) | 2.75 | BUY |
| SMA (30) | 2.70 | BUY |
| EMA (50) | 2.69 | BUY |
| SMA (50) | 2.71 | BUY |
| EMA (100) | 2.58 | BUY |
| SMA (100) | 2.56 | BUY |
| EMA (200) | 2.43 | BUY |
| SMA (200) | 2.45 | BUY |
About Protalix BioTherapeutics, Inc.
Healthcare · Biotechnology
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-10-08
Stop 2.67 Now 3.06 Target 2.76
🟡 BULLISH LEAN
The main driver: outperforming the market by 19.4%, RSI in healthy zone. More signals pointing up than down. Not full confluence yet, but the weight of evidence is bullish. Use `!alert PLX [level]` to catch the entry, or `!plan PLX` to size small.
Scores: 3 bullish / 0 bearish
Scored without analyst — data unavailable this render.
No real edge — avoid
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 64 |
| ⏰ 4H | RANGING | 38 |
| 🕐 1H | BULLISH | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NEUTRAL 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.